Products for Research Use Only
RegisterLogin

Panulisib

CAT: 0804-HY-16769Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-16769Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Panulisib (P7170; AK151761) is an orally active inhibitor of PI3K (IC50 = 2.2 nM) and mTOR (IC50 = 4.4 nM) . Panulisib inhibits ALK1 and DNA-PK, two enzymes that respectively participate in angiogenesis and DNA repair, with IC50 values of 47 nM and 1.5 nM respectively. Panulisib inhibits cell proliferation and apoptosis. Panulisib can be used for research on breast cancer and non-small cell lung cancer[1][2][3].
CAS Number
1356033-60-7
Product Name Alternative
P7170; AK151761
UNSPSC
12352005
Target
Anaplastic lymphoma kinase (ALK) ; Apoptosis; DNA-PK; mTOR; PI3K
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK
Field of Research
Cancer
Smiles
N#C/N=C(N1C2=CC=C(C(C)(C#N)C)N=C2)\N(C)C3=C1C4=CC(C5=CC(C(F)(F)F)=C(N)N=C5)=CC=C4N=C3
Molecular Formula
C27H20F3N9
Molecular Weight
527.50
References & Citations
[1]Jalota-Badhwar A, et al. P7170: A Novel Molecule with Unique Profile of mTORC1/C2 and Activin Receptor-like Kinase 1 Inhibition Leading to Antitumor and Antiangiogenic Activity. Mol Cancer Ther. 2015 May;14 (5) :1095-106.|[2]Bean JR, et al. The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer. Breast Cancer Res Treat. 2015 Jan;149 (1) :69-79. |[3]Venkatesha VA, et al. P7170, a novel inhibitor of mTORC1/mTORC2 and Activin receptor-like Kinase 1 (ALK1) inhibits the growth of non small cell lung cancer. Mol Cancer. 2014 Dec 2;13:259.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Alternative Products

CatalogName
GEC03360-01Panulisib
A14379-5Panulisib 5mg
A14379-10Panulisib 10mg
MBS3840331Panulisib (P7170, AK151761)

Popular Products